AbbVie Inc. logo

ABBV

AbbVie Inc.

PharmaceuticalsDrug Manufacturers$398B Market Cap

Pharmaceutical company with focus on immunology and virology. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
15%Bearish
Buy/Sell Ratio16% buys
BearishBullish
AbbVie Inc. Live QuoteDaily Close
$287.52
+$2.33(+0.82%)1M
Day Range$284.85 – $290.23
Open$287.02
Previous Close$283.54
Volume8.76M
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$501.19B
P/E Ratio (TTM)48.7
Forward P/E17.6
EPS (TTM)$5.82
Price to Book50.5
Dividend Yield2.42%
Beta (Volatility)0.19
IndustryDRUG MANUFACTURERS - GENERAL
52-Week RangeCurrent: $287.52 (87%)
Low: $188.25High: $302.93
Wall Street Consensus
Strong Buy
Analyst Rating
4.8/ 5.0
Target Price
$315.88+40.3% upside

Insider Buys

3

$18.98M

Insider Sales

16

$99.93M

Total Volume

$118.92M

32 transactions

Net Activity

$80.95M

Net selling

Proprietary Ratings
Calculated from Form 4 transactions
85CONFIDENCE

Sentiment Rating

Strong Accumulation

CEO Conviction Index

High Conviction Accumulation

Key Drivers

  • •Heavy distribution: sales represent 84% of total transaction value.
  • •Cluster buying: 3 unique insiders purchased shares, showing strong alignment.
  • •CEO buying activity detected. When chief executives put their own money at risk, it is historically a strong bullish signal.
  • •CFO buying activity detected. Statistical studies show CFO purchases have high predictive power due to their direct visibility into balance sheet details.
  • •Ultra-high accumulation: total purchase value exceeds $10M.
  • •Significant liquidation: total sale value exceeds $10M.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
S
1

Stewart Jeffrey Ryan

EVP, CHIEF COMMERCIAL OFFICER

0 buys2 sells

$24.29M total

G
2

Gonzalez Richard A

Dir

0 buys1 sells

$20.26M total

S
3

Siatis Perry C

EVP, GC, SECRETARY

0 buys4 sells

$16.49M total

D
4

Donoghoe Nicholas

EVP, CHIEF BUS, STRAT OFFICER

0 buys2 sells

$10.82M total

R
5

Richmond Timothy J.

EVP, CHRO

0 buys2 sells

$10.54M total

Trading History
ABBV insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Nov 9, 2026

1 weeks ago

Stewart Jeffrey Ryan

EVP, CHIEF COMMERCIAL OFFICER

EVP
Sell40.6K$293.60$11.93M

Oct 22, 2026

4 weeks ago

Richard Gonzalez

CEO

CEO
Buy18.1K$223.65$4.04M

Oct 19, 2026

1 months ago

Board Director

Dir

Director
Buy20.3K$228.21$4.64M

Oct 3, 2026

1 months ago

Roberto Zalka

CFO

CFO
Buy43.7K$235.69$10.30M

Aug 14, 2026

3 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell74.4K$-32710.00$0

Aug 14, 2026

3 months ago

Donoghoe Nicholas

EVP, CHIEF BUS, STRAT OFFICER

EVP
Sell32.7K$250.00$8.18M

Mar 4, 2026

8 months ago

Purdue David Ryan

SVP, Controller

SVP
Sell5.2K$233.56$1.22M

Mar 4, 2026

8 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell3.2K$-5230.00$0

Mar 2, 2026

8 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell4.6K$-18668.00$0

Mar 2, 2026

8 months ago

Siatis Perry C

EVP, GC, SECRETARY

EVP
Sell18.7K$234.39$4.38M

Feb 25, 2026

8 months ago

Siatis Perry C

EVP, GC, SECRETARY

EVP
Sell22.4K$230.00$5.15M

Feb 25, 2026

8 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell38.1K$-22381.00$0

Aug 12, 2025

15 months ago

Saleki-Gerhardt Azita

EVP, CHIEF OPERATIONS OFFICER

EVP
Sell42.4K$198.42$8.41M

Aug 12, 2025

15 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell183.8K$-42370.00$0

Aug 5, 2025

15 months ago

Donoghoe Nicholas

EVP, CHIEF BUS, STRAT OFFICER

EVP
Sell13.3K$198.51$2.64M

Aug 5, 2025

15 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell58.2K$-13295.00$0

Mar 31, 2025

19 months ago

Stewart Jeffrey Ryan

EVP, CHIEF COMMERCIAL OFFICER

EVP
Sell58.8K$210.08$12.36M

Mar 31, 2025

19 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell54.6K$-58832.00$0

Mar 14, 2025

20 months ago

Reents Scott T

EVP, CFO

CFO
Sell17.6K$212.34$3.75M

Mar 14, 2025

20 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell11.6K$-17644.00$0

Feb 28, 2025

21 months ago

Gonzalez Richard A

Dir

Director
Sell98.6K$205.45$20.26M

Feb 28, 2025

21 months ago

Siatis Perry C

EVP, GC, SECRETARY

EVP
Sell27.9K$208.69$5.82M

Mar 3, 2025

20 months ago

Richmond Timothy J.

EVP, CHRO

EVP
Sell21.3K$210.45$4.47M

Feb 28, 2025

21 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell388.9K$-98628.00$0

Mar 3, 2025

20 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell6.1K$-21250.00$0

Feb 26, 2025

21 months ago

Richmond Timothy J.

EVP, CHRO

EVP
Sell29.9K$202.90$6.07M

Feb 26, 2025

21 months ago

Buckbee Kevin K

SVP, CONTROLLER

SVP
Sell18.9K$203.41$3.85M

Feb 26, 2025

21 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell11.5K$-18944.00$0

Feb 20, 2025

21 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell22.4K$-5778.00$0

Feb 20, 2025

21 months ago

Siatis Perry C

EVP, GC, SECRETARY

EVP
Sell5.8K$197.90$1.14M

Dec 16, 2024

23 months ago

Buckbee Kevin K

SVP, CONTROLLER

SVP
Sell1.8K$172.24$310K

Dec 16, 2024

23 months ago

Multiple Insiders

S - Sale+OE Insiders

Insider
Sell7.0K$-1800.00$0
Sector & Industry Benchmarks
Pharmaceuticals Comparison Overview
Industry Buy Conviction0%
ABBV Buy Conviction16%
Industry Rank#1 of 1
Volume Contribution997.1%
Total Industry Activity$11.93M

ABBV has an insider buy conviction of 16%, compared to the Pharmaceuticals sector buy average of 0%. ABBV ranks #1 in insider activity out of 1 tracked companies in its industry.

Insider Trading Summary & Commentary
Automated executive transaction analysis for ABBV

Over the last 90 days, corporate insiders at AbbVie Inc. (ABBV) engaged in a total of 32 transactions reported via SEC Form 4 filings. Among these, 3 were open-market purchases and 16 were sales. The total volume of insider trading reached $118.92M.

The net insider activity for ABBV shows a net selling bias of $80.95M. This activity represents a 16% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Sale by Gonzalez Richard A (Dir), who traded 98.6K shares valued at $20.26M on Feb 28, 2025.

Live Market News & Developments
Aggregated real-time headlines for AbbVie Inc. (ABBV)
6 updates

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?

The Motley Fool7h ago

AbbVie (ABBV) Stock Climbs As Q3 Earnings Fuel Growth Case

Yahoo Finance16d ago

AbbVie inks up to $2.54B bispecific cancer drug deal with DISCO Pharma

Seeking AlphaYesterday

AbbVie (ABBV) Stock Still Looks Cheap On Its 197% Five Year Run

Yahoo Finance22d ago

Billionaire Ken Griffin Increased His Stake in This Dividend King by 547% in Q2. Wall Street Thinks It's Still a Buy.

The Motley Fool86d ago

AbbVie (ABBV) Stock May Be 41% Undervalued Following JUVMO Approval

Yahoo Finance50d ago

Explore Peers in Drug Manufacturers

Compare insider activity and sentiment scores across similar organizations.

FAQs About AbbVie Inc. Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for ABBV.

Based on SEC Form 4 disclosures, the Insider Confidence Score for ABBV is currently 85/100, which reflects a strong accumulation bias. This calculation accounts for a total of 3 purchases and 16 sales by company executives over the last 90 days.

The CEO Conviction Index for ABBV is rated as "High Conviction Accumulation". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.